Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 291,000	$ 634,000	$ 519,000
Operating expenses:
Research and development	39,640,000	44,953,000	27,237,000
Research and development – related party		795,000	2,347,000
General and administrative	11,333,000	9,906,000	9,077,000
Total operating expenses	50,973,000	55,654,000	38,661,000
Operating loss	(50,682,000)	(55,020,000)	(38,142,000)
Other income (loss)		(22,000)	(838,000)
Other expense – related party	(190,000)		(392,000)
Interest income	117,000	87,000	40,000
Interest expense	(3,092,000)	(398,000)	(108,000)
Interest expense, net – related party			(1,667,000)
Loss before income taxes and noncontrolling interest	(53,847,000)	(55,353,000)	(41,107,000)
Income tax provision	800,000	0	0
Net loss before noncontrolling interest	(54,647,000)	(55,353,000)	(41,107,000)
Less: net loss attributable to noncontrolling interest	(38,503,000)	(39,001,000)	(13,609,000)
Net loss attributable to vTv Therapeutics Inc.	$ (16,144,000)	$ (16,352,000)	$ (27,498,000)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (1.67)	$ (1.71)	$ (3.32)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	9,693,254	9,545,527	8,276,520